New hope of extraterrestrial life? Scientists cautious about celebrating early, want recheck
Are we alone in this universe? A study led by the University of Cambridge provides a flicker of hope that it may not be so, and the answer may lie 120 light-years from Earth. The study, published in the Astrophysical Journal Letters last week, found hints of life in the distant planet named K2-18b. But astrophysicists are sceptical and say the study's results and the methodology need to be cross-checked by other researchers. According to the research, fingerprints of dimethyl sulphide and dimethyl disulphide molecules have been detected on the exoplanet's atmosphere. On Earth, these molecules are known to be produced by marine organisms.
Interestingly, the most common hypothesis is that life on Earth originated in the ocean.
The study provides evidence of 'three-sigma' significance -- a 99.7 per cent confidence that the results are not fortuitous -- about the strongest-yet of signs of life outside the Solar System, asserts the research team led by Nikku Madhusudhan, a professor of astrophysics and exoplanetary science. In an interview with PTI Videos last week, he said that given scope of the study's implications, his team was looking to increase the robustness of the results in future researches.
Jayesh Goyal, a reader at the School of Earth and Planetary Sciences at the National Institute of Science Education and Research (NISER), Bhubaneswar, feels that the findings of the study are a big step forward and "pushes the limits of our understanding of exoplanet atmospheres and their habitability". "The observations on K2-18b's atmosphere highlight the extent to which this class of sub-Neptune or super-earth exoplanets could be characterised as these targets are extremely challenging to study," he told PTI. The exoplanet is 8.6 times massive than Earth, but smaller and less massive than Neptune. Hence it has been classified as a 'sub-Neptune' exoplanet. Scientists who study exoplanets contest the interpretation of the observations, saying the results are not statistically sound, given the immensity of claims of detecting biological activity outside the Solar System.
"It is not a 'detection' according to the usual standards of exoplanet science," Ryan MacDonald, NASA Sagan Fellow at the University of Michigan in the US, told PTI.
Data recorded by the James Webb Space Telescope's MIRI instrument was analysed for the study. The infrared facility looked at starlight transmitted through the exoplanet's atmosphere. "The study assumes that half of the new data from the Webb telescope can only be explained by dimethyl sulphide and dimethyl disulphide, neglecting other possible gases, thereby attaching a much higher statistical significance to the claims than the data supports," the astronomer said. Asa Stahl, an astrophysicist whose PhD at the US' Rice University focused on exoplanets, said the study made use of a "hugely powerful tool" for peering into a faraway planet's atmosphere. "It's an immensely difficult task -- trying to piece together what a planet over a hundred light years away is like from how starlight filters through its atmosphere." However, it is also a relatively new method, and astronomers are still figuring out the best practices for this sort of thing, added Stahl, engaged in science communication projects. Madhusudhan, while asserting that the team of researchers would look into fortifying the robustness of the study's results, also said, "When you have big breakthroughs and big paradigm shifts, you want to be really sure because it changes the very fabric of science and society in fundamental ways." "So then, the measure of robustness there is that we want to be sure to a level that there is less than one part in a million chance of a fluke, which is a very, very, very small chance of a statistical fluke or a 'just by chance'. We want to be that robust," he added. However, the currently claimed 'three-sigma' significance -- or a 0.3 per cent of being wrong -- would need to be tested, astrophysicists said. "Using the statistics in the study, the actual probability of the molecules not being present (in K2-18b's atmosphere) is about 28 per cent. Therefore, the announcement projects (a) near-absolute confidence in a result that has a good chance of not being real," MacDonald said. And same is the case with Stahl. "We won't know for sure how robust the finding is until other researchers test it."
Astrophysicist Stephen Schmidt, a graduate research fellow at the Johns Hopkins University, US, re-analysed results from a 2023 study, in which Madhusudhan's team, using the James Webb space telescope, found abundant levels of carbon-containing gases -- methane and carbon dioxide -- and potential signs of dimethyl sulphide. Despite replicating the models used in the 2023 study, the results of the re-analysis (currently in a pre-print paper stage) differed from the original. Schmidt's team could not put limits on detectable amounts of carbon dioxide in K2-18b's atmosphere. The result indicated "a lot more methane compared to carbon dioxide" and therefore, "very difficult and unlikely for the exoplanet to have a habitable liquid water surface ocean, and also a biosphere or life", he explained. Schmidt said that while the University of Cambdrige-led study pushes the limits and tests the capabilities of the Webb telescope, which he stresses is important, "this can result in potentially exciting findings that aren't substantiated after further observations." Further, there are questions that need answers, to know for sure what is happening. One of these involves understanding the processes through which dimethyl sulphide and dimethyl sulphide molecules -- considered as predictors of life on exoplanets -- can form. Even as Madhusudhan's team is looking to address this aspect in future research, answers to the origins of the molecules could prove to be especially important as studies have found dimethyl sulphide on a comet and in the space between stars -- both 'lifeless' environments. Goyal said more observations of K2-18b using the Webb telescope, along with a detailed study of laboratory spectra of dimethyl sulphide and dimethyl disulphide, could help tighten or dispute the study's results. Further, a model's ability to detect chemicals accurately should be quoted in a paper, after "considering a wide variety of different molecules, rather than just those one assumes are there," MacDonald said. The astrophysicists said not one chemical or molecule, but a combination of chemicals or gases, produced in significant amounts, along with a deep understanding of the exoplanet's environment, would be needed before being confident of habitability.
However, the methods used in the Cambridge-led study could hold promise in these pursuits. Stahl said, "If we ever discover life in another world, this method could be how we find out."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
3 hours ago
- Hindustan Times
The Alzheimer's drug pipeline is healthier than you might think
OF ALL THE medical challenges that scientists have faced, Alzheimer's disease, the most common form of dementia, has been one of the trickiest. Between 1995 and 2021 private money spent on Alzheimer's research totalled $42.5bn, but more than 140 trials failed to deliver a single drug capable of slowing the disease. Yet the tide may be turning. There are two working drugs, offering modest benefits, on the market. A new review paper suggests more could soon follow. There are 182 clinical trials for Alzheimer's treatments under way in 2025—an 11% increase on the previous year—testing 138 different drugs, of which 12 are set to complete their final 'phase 3' trials this year. Moreover this pipeline includes medicines aimed at a diverse range of targets in the brain, reflecting an increasingly sophisticated understanding of the molecular processes behind Alzheimer's and dementia more broadly. For decades, the theory that has dominated Alzheimer's research, and drug pipelines, is known as the amyloid hypothesis. It argues that the primary cause of the disease is the accumulation of plaques of beta-amyloid proteins in the brain. These would lead to a cascade of negative effects including neuronal dysfunction, brain-cell death and neuroinflammation. The amyloid hypothesis was supported by genetic evidence, which showed mutations in key genes within families to be linked to early onset of the disease. The success of the two drugs already treating Alzheimer's—lecanemab and donanemab, which arrived on the market in 2023 and 2024, respectively—proves that a connection exists. Both help to clear amyloid from the brain, and offer modest help to a subset of patients for whom the drug is thought to be safe and useful. They slow the progression of the disease by about one-third, according to clinical trials, meaning patients can retain their quality of life for longer. The excitement generated by these drugs was tinged, however, with a feeling that they were not much to show for decades of effort. The singular focus on amyloid was probably misplaced. James Rowe, a professor of cognitive neurology at the University of Cambridge, says that although amyloid accumulation is a critical 'early trigger' for the disease, by the time patients arrive at his clinic there are other neural processes accelerating the illness. These include the accumulation of a misshapen version of a protein called tau; increased metabolic stress on brain cells; neuroinflammation; and degeneration of the brain's blood supply. A more nuanced understanding of Alzheimer's is at last being reflected in drug development. That is the conclusion of Jeffrey Cummings at the University of Nevada, Las Vegas, and colleagues in a review published on June 3rd in the journal Translational Research & Clinical Interventions. Academic experts, and investors, agree. Dame Kate Bingham is the managing partner of SV Health Investors, a venture-capital firm based in London that in 2015 started the first fund dedicated to discovering new treatments for dementia in 2015. At the time the drug pipeline for Alzheimer's was mainly focused on tackling amyloid. She says the growing diversity of potential targets today gives her increased optimism. Fully one-third of the new drugs are repurposed, which means they are already approved for use in other conditions and are being redeployed to Alzheimer's. The appeal of this approach is that the drugs already have known safety and toxicity profiles, and can be approved quickly and developed cheaply. One of the more well-known is semaglutide, a diabetes and weight-loss drug whose anti-inflammatory and metabolic benefits have led to its being tested as a treatment for mild cognitive impairment. The drug piromelatine, meanwhile, works on melatonin and serotonin receptors in the brain, which help regulate sleep. As healthy sleep is thought to increase the rate at which amyloid and other waste proteins are cleared, improving it may slow the progression of Alzheimer's. Then there is AR1001 (also known as mirodenafil), which was originally developed for erectile dysfunction and is being tested for its neuroprotective properties. The drug increases levels of a molecule in the brain called cGMP which, in turn, activates pathways that support the survival of nerve cells and improve connections between brain cells. Drugs in this category are known to improve blood flow, so the drug might also have an impact on the brain's vascular health. Another repurposed drug is nabilone, which interacts with the cannabinoid receptors in the body. (The most well known molecule of this kind is tetrahydrocannabinol, the active compound in cannabis). It was originally developed to treat nausea and vomiting in those undergoing cancer chemotherapy. It is now being tested as a potential treatment for agitation and behavioural problems in those with Alzheimer's. Guanfacine, a drug that improves attention and executive function in those with ADHD, is also being tested to see if it can offer similar benefits. Repurposed drugs do not necessarily have a higher chance of success in late-stage trials than those with a novel mechanism. Dame Kate argues that innovative approaches that use new molecular targets, rather than repurposing, will have the greatest impact on the disease. One area of innovation centres around drugs that can tackle inflammation in the brain. Particular attention is being paid to brain cells called microglia, which play a central role in the brain's immune response and, most probably, its fight against Alzheimer's. Microglia have been described as acting as the brain's fire service, police and binmen, because they respond to emergencies, maintain order and clear up debris. A number of drugs are trying to target the protein TREM2 on the surface of microglia in the hope of boosting their activity. Combinations of drugs are also being tested. For example, it is hoped that a pairing of dasatinib, a cancer drug, and quercetin, a molecule derived from plants, will clear ageing and dysfunctional cells. Drug combinations that target different pathways and components of an illness have made big inroads into other complex and intractable diseases such as cancer and HIV. Some of the errors of the past have been corrected. Dr Rowe says that early attempts to design amyloid-clearing drugs did not remove enough amyloid, or did so too slowly. The patient selection in trials was also poor, with many patients included who—it later turned out—did not have Alzheimer's at all. Today's trials still have blind spots, warns Antonella Santuccione-Chadha, the founder of the Women's Brain Foundation, a non-profit that studies how sex affects brain and mental health. Many still fail to differentiate patients by sex, she says. Yet women are twice as likely to develop Alzheimer's, a difference that cannot be explained solely by their longer lifespans, and the disease seems to progress differently in their brains. At any given stage of the disease, tau proteins spread farther in women than in men, says Dr Chadha. It would help the trials—and patients—if more people were tested for Alzheimer's earlier on, so that they could be enrolled to try the new drugs. A single register of those with the disease would also be useful, making it easier for patients to find trials, and for drug companies to find patients. Much, therefore, remains to be done. But for those suffering from a horrible and as yet insurmountable disease that steals so many minds, there is also some much needed hope. Curious about the world? To enjoy our mind-expanding science coverage, sign up to Simply Science, our weekly subscriber-only newsletter. Get 360° coverage—from daily headlines to 100 year archives.
NDTV
10 hours ago
- NDTV
James Webb Telescope Detects Frozen Water In Young Star System For The First Time
For decades, scientists have been fascinated by the mystery of how life originated on Earth and where our water came from. One long-standing theory suggests that water was present around our star, particularly in the outer reaches of the solar system in its early days. Recently, NASA researchers using the James Webb Space Telescope made a groundbreaking discovery that lends credence to this theory. They've found water ice in the debris disk that orbits HD 181327, a Sun-like star 155 light-years from Earth. According to Science Alert, the star system, just 23 million years old, is significantly younger than our 4.6-billion-year-old Solar System. This youthful system is still in its formative stages, with a protoplanetary disk surrounding the star that hasn't yet coalesced into planets. Chen Xie, an assistant research scientist at JHU and the study's lead author, said in a recent NASA press release, "Webb unambiguously detected not just water ice, but crystalline water ice, which is also found in locations like Saturn's rings and icy bodies in our Solar System's Kuiper Belt. The presence of water ice helps facilitate planet formation. Icy materials may also ultimately be 'delivered' to terrestrial planets that may form over a couple of hundred million years in systems like this." Using the James Webb Space Telescope's near-infrared spectrograph (NIRSpec), researchers detected water ice in the debris disk surrounding HD 181327. The water ice was predominantly found in the outer debris ring, making up over 20% of its mass, in the form of "dirty snowballs", a combination of ice and fine dust particles. The amount of water ice decreased closer to the star, with only 8% of the material consisting of ice halfway in from the disk's edge, and virtually none near the centre. This decrease is likely due to vaporisation from the star's ultraviolet radiation or potentially locked up in rocks and planetesimals. "When I was a graduate student 25 years ago, my advisor told me there should be ice in debris disks, but before Webb, we didn't have instruments sensitive enough to make these observations. What's most striking is that this data looks similar to the telescope's other recent observations of Kuiper Belt objects in our own Solar System," said Christine Chen, an associate astronomer at the Space Telescope Science Institute (STScI) and co-author on the study. Analysing these actively forming planetary systems will enhance our understanding of planet formation models and provide fresh insights into the origins of our own Solar System.
Economic Times
12 hours ago
- Economic Times
Is Europa, Jupiter's ocean moon, the final haven for life once the sun dies? Here's what a recent study shows
In approximately 4.5 billion years, as the sun transforms into a red giant and engulfs Earth, Jupiter's moon Europa may offer a temporary refuge. Research suggests Europa's icy shell will sublimate, potentially creating a fleeting water vapor atmosphere lasting up to 200 million years. This could provide a brief window for habitable conditions and detectable biosignatures. Tired of too many ads? Remove Ads How does the red giant sun affect Europa? Tired of too many ads? Remove Ads Can Europa's oceans survive the heat? What are the chances of finding life or biosignatures? FAQs The most intriguing question is what will happen to life in our solar system after the sun sun will become a red giant and wipe out Earth in roughly 4.5 billion years. The cold moons of the outer solar system may provide humanity a fleeting chance to survive, while new science offers us a glimpse of a distant, dying future. Europa , one of Jupiter's moons, might serve as a temporary safe at Cornell University's Carl Sagan Institute reached this conclusion and published their findings in the journal Monthly Notices of the Royal Astronomical sun will reach the end of its life cycle in roughly 4.5 billion years. Its hydrogen fusion core will grow, inflating the star's outer atmosphere to enormous proportions. It will enlarge and turn into a red giant star, burning up Earth and swallowing up Venus and Mercury, as per a report by the sun enters this new stage of life, the habitable zone, the region where the radiation influx is just right to support liquid water on a planet's surface, will gradually move Jupiter remains an inhospitable giant ball of gas, some of its moons could potentially lead to a habitable the ice-covered moon of Jupiter, will receive a lot of heat. Jupiter will become hotter and reflect more sunlight, which will give the small moon its own source of heat besides the giant sun's scientists discovered that the oceans below will evaporate while the icy outer shell sublimates. Because it will receive the most heat, the side of Europa facing Jupiter will experience the most sublimation, as per a report by the anti-Jupiter side of Europa, the rate of water loss will be slower in the northern and southern latitudes. According to the researchers, this might produce a thin layer of water vapor that lasts for 200 million years or researchers discovered that biosignatures may be detectable on icy moons of red giant stars. Although there are a number of promising candidates, we have not yet detected any exomoons with resolving power to investigate these moons' atmospheric features may come from future observations using the James Webb Space Telescope or the proposed Habitable Worlds Observatory. Even though the likelihood of finding life is narrow, it does expand the range of potential places for our search because there might still be refuges around almost-dead but only for a short time up to 200 million years in isolated areas where water loss is underground oceans and temporary water vapor atmosphere may provide brief habitable conditions.
